Polygenic scores in biomedical research
- PMID: 35354965
- PMCID: PMC9391275
- DOI: 10.1038/s41576-022-00470-z
Polygenic scores in biomedical research
Abstract
Public health strategies aimed at disease prevention or early detection and intervention have the potential to advance human health worldwide. However, their success depends on the identification of risk factors that underlie disease burden in the general population. Genome-wide association studies (GWAS) have implicated thousands of single-nucleotide polymorphisms (SNPs) in common complex diseases or traits. By calculating a weighted sum of the number of trait-associated alleles harboured by an individual, a polygenic score (PGS), also called a polygenic risk score (PRS), can be constructed that reflects an individual’s estimated genetic predisposition for a given phenotype. Here, we ask six experts to give their opinions on the utility of these probabilistic tools, their strengths and limitations, and the remaining barriers that need to be overcome for their equitable use.
Conflict of interest statement
Competing interests
C.M.L. is a member of the Scientific Advisory Board for Myriad Neuroscience. A.R.M. has consulted for 23andMe and Illumina and received speaker fees from Genentech, Pfizer and Illumina. The other contributors declare no competing interests.
References
-
- Polygenic Risk Score Task Force of the International Common Disease Alliance. Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps. Nat. Med 27, 1876–1884 (2021). - PubMed
RELATED LINKS
-
- Clinical Genome Resource (ClinGen) Complex Disease working Group: https://www.clinicalgenome.org/working-groups/complex-disease/
-
- eMERGE Network: https://emerge-network.org/
-
- Global Biobank Meta-analysis initiative: www.globalbiobankmeta.org
-
- International Consortium for Integrative Genomics Prediction: www.interveneproject.eu
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
